secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2022-09-08T23:59:59+00:00
Accession:  0000950170-22-018243
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista Q1 net loss $23.0M ($0.94/share); cash $142.1M, down $24.1M from April
-------------------------------------------------------------------------------

- No revenue; R&D spending rose to $18.2M (vs. $13.7M a year ago), driven by Phase 3 KONFIDENT and preclinical costs.
- Net loss widened to $23.0M from $16.1M; cash burn reflects higher operating expenses.
- KVD824 Phase 2 KOMPLETE trial passed 50% enrollment; top-line data expected mid-2023.
- Open-label extension (KONFIDENT-S) initiated for sebetralstat; Phase 3 KONFIDENT data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022018243/0000950170-22-018243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017022018243/kalv-20220908.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer